NCT03249597

Predict Sepsis; the Predictive Value of Bedside Measures in the Ambulance

Completed Last updated 27 October 2020

What this trial tests

trial testing Blood test: Glukos, SuPAR, Laktat and HBP in Sepsis in 956 participants. Completed in 30 August 2018.

Timeline

3 April 2017

Primary endpoint
30 August 2018

30 August 2018

Quick facts

Lead sponsor	Karolinska Institutet
Status	Completed
Study type	OBSERVATIONAL
Enrollment	956
Start date	3 April 2017
Primary completion	30 August 2018
Estimated completion	30 August 2018
Sites	1 location across Sweden

Drugs / interventions tested

• Blood test: Glukos, SuPAR, Laktat and HBP

Conditions studied

• Sepsis — all drugs for Sepsis →
• Sepsis Syndrome — all drugs for Sepsis Syndrome →
• Sepsis, Severe — all drugs for Sepsis, Severe →

Sponsor

Karolinska Institutet

Who can join

18 and older, any sex, with Sepsis or Sepsis Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sepsis is a condition with a high mortality. Septic patients are frequently difficult to identify because of their non-specific presentations. There is also a low sensitivity of clinical judgment among health care personnel, and of existing screening tools, which are in turn typically based on vital parameters. Despite prior research, no unique sepsis biomarker has been identified so far.

There is a need for new strategies to identify sepsis which do not rely on vital parameters and traditional laboratory blood tests alone. The hypothesis of the investigators is that a combination of clinical variables measurable in the ambulance can be used to predict sepsis.

The aim of the current study is to determine the predictive value of keywords related to symptom presentation, vital parameters and point-of-care (POC) blood tests, alone and in combination, with respect to the outcome sepsis.

The study is performed in the Stockholm ambulance setting from April 2017. A total of 956 adult non-trauma patients will be included.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group.
   Velissaris D, Dimopoulos G, Parissis J, Alexiou Z, et al · · 2020 · cited 20× · PMID 32399855 · DOI 10.1007/s40121-020-00301-w
2. The predictive value of variables measurable in the ambulance and the development of the Predict Sepsis screening tools: a prospective cohort study.
   Wallgren UM, Sjölin J, Järnbert-Pettersson H, Kurland L. · · 2020 · cited 15× · PMID 32586337 · DOI 10.1186/s13049-020-00745-6
3. Performance of NEWS2, RETTS, clinical judgment and the Predict Sepsis screening tools with respect to identification of sepsis among ambulance patients with suspected infection: a prospective cohort study.
   Wallgren UM, Sjölin J, Järnbert-Pettersson H, Kurland L. · · 2021 · cited 8× · PMID 34593001 · DOI 10.1186/s13049-021-00958-3
4. Predicting sepsis using a combination of clinical information and molecular immune markers sampled in the ambulance.
   Tuerxun K, Eklund D, Wallgren U, Dannenberg K, et al · · 2023 · cited 7× · PMID 37691028 · DOI 10.1038/s41598-023-42081-6
5. Exploring the circulating metabolome of sepsis: metabolomic and lipidomic profiles sampled in the ambulance.
   Salihovic S, Eklund D, Kruse R, Wallgren U, et al · · 2024 · cited 2× · PMID 39369060 · DOI 10.1007/s11306-024-02172-5
6. Association between variables measured in the ambulance and in-hospital mortality among adult patients with and without infection: a prospective cohort study.
   Wallgren UM, Järnbert-Pettersson H, Sjölin J, Kurland L. · · 2022 · cited 2× · PMID 36418966 · DOI 10.1186/s12873-022-00746-x